Akebia Therapeutics (AKBA) Proxy filing summary

Voting matters and shareholder proposals

• Election of three Class III directors to serve until the 2029 annual meeting, with nominees Adrian Adams, Michael Rogers, and LeAnne M. Zumwalt recommended for election.

• Proposal to amend the certificate of incorporation to increase authorized capital stock to 525,000,000 shares and common stock to 500,000,000 shares.

• Advisory approval of named executive officer compensation as described in the proxy statement.

• Advisory vote on the frequency of executive compensation votes, with a recommendation for annual (1 year) frequency.

• Ratification of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.

Board of directors and corporate governance

• Three Class III director nominees are up for election to serve five-year terms, subject to earlier death, resignation, or removal.

Executive compensation and say-on-pay

• Advisory vote sought on executive compensation, with board recommending approval of the compensation of named executive officers.

• Advisory vote on the frequency of future say-on-pay votes, with a recommendation for annual votes.